NetworkNewsBreaks Archive - Page 2109 of 2220

ThursdayJul 06, 2017 10:21 am

NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Included in the Horizons Medical Marijuana Life Sciences ETF

ABcann Global Corporation (TSXV: ABCN) yesterday announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF is a first-of-its-kind index offering investors direct exposure to a basket of North American life sciences companies with significant business activities in the medical marijuana sector. “The Horizons ETF represents a new type of investment, a fund that tracks an industry in which there is considerable interest but which had no prior investment vehicle through which investors could gain broad exposure,” Aaron Keay, CEO of ABcann, stated in the news release. “Our inclusion in the ETF represents an important…

WednesdayJul 05, 2017 1:21 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on July 5, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: DCIX 372.29% – News: Settles $148M secured loan facility with RBS with payment of $85M NWGI 35.80% – News: Obtains required certification for betting software platform CERU 32.09% – News: Issues letter to stockholders CLSN 23.27% – News: Completes OVATION study; provides update on immunotherapy trial BLFS 10.43% – News: Reaches agreement to modify existing credit facility SWEE 8.33% – News: Receives GRAS confirmation from independent panel regarding BESTEVIA™ Reb-D MTBC 7.63% – News:…

WednesdayJul 05, 2017 12:10 pm

NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Surges on Positive Guidance from FDA for DCCR in Prader-Willi Syndrome

Soleno Therapeutics (NASDAQ: SLNO) shares are up 11% on news that the company has received the minutes from a scientific advice meeting from the U.S. Food and Drug Administration (FDA) regarding Diazoxide Choline Controlled-Release (DCCR) for the treatment of Prader-Willi syndrome (PWS). The company previously submitted data from a phase II study of DCCR in PWS patients, as well as data from other studies conducted with DCCR. The company agreed with the FDA’s suggestion that the duration of the study should be shorter and that DCCR safety information could be obtained in a long-term, safety extension study. Soleno said it…

WednesdayJul 05, 2017 12:07 pm

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Takes Delivery of Its Second Modern Newcastlemax Vessel; Shares Higher

Shares of DryShips (NASDAQ: DRYS) are up 12% mid-day after the company earlier said it has taken delivery of its previously announced 205,123 DWT Newcastlemax drybulk vessel. The vessel, which is the second for the owner of ocean-going cargo vessels, was built in 2013. Per a previous agreement, the vessel will be employed under a time charter contract with a major coal and steel trader for a gross rate linked to the new Baltic Capesize Index (BCI5TC) plus 20%. To view the full press release, visit: http://nnw.fm/1v0SD About DryShips Inc. The company is a diversified owner of ocean going cargo…

WednesdayJul 05, 2017 11:45 am

NetworkNewsBreaks – Aegis Capital Issues ‘Buy’ Rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital has issued a ‘Buy’ rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), citing the company’s recent filing of a Post-Grant Review (PGR) against Incyte Corporation’s (NASDAQ: INCY) U.S. Patent No. 9,662,335. The patent includes claims relating to Janus kinase inhibitors (JAKs), which affects Concert's deuterated ruxolitinib CTP-543, an oral JAK 1/2 inhibitor designed to treat alopecia areata. The analyst believes that the PGR process could resolve IP issues early, and the company appears confident in its case. For more information, visit www.concertpharma.com About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated…

WednesdayJul 05, 2017 11:43 am

NetworkNewsBreaks – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) Has “Buy” Rating Reiterated at Aegis Capital

Aegis Capital reiterated a ‘Buy’ rating and price target of $41 on shares of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) following the company’s recent report that eptinezumab met the primary and key secondary endpoints in PROMISE 1, a phase 3 pivotal clinical trial evaluating patients with frequent episodic migraine. The analyst noted that this positive news pushes the company one step closer to FDA approval for eptinezumab. Additionally, an upcoming catalyst for the company is the PROMISE 2 data expected in the first half of 2018. For more information, visit www.alderbio.com About Alder BioPharmaceuticals Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…

FridayJun 30, 2017 2:12 pm

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) Announces Availability of Green Leaf Farms Rosin Products at Las Vegas Dispensary

Player’s Network, Inc. (OTCQB: PNTV) today announced the availability of its Green Leaf Farms rosin products at the Pisos Dispensary, located just a few miles from the Las Vegas Strip. “This day has been a long time coming. It marks both the end of prohibition and the true beginning of mass distribution for Green Leaf Farms products,” Mark Bradley, CEO of Player’s Network, stated in the news release. “Our products are now available at the Pisos Dispensary in Las Vegas, as well as in top notch dispensaries in Henderson. We are aggressively moving on the opportunities provided by this growing…

FridayJun 30, 2017 1:19 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 30, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SPI 38.58% – News: Successfully completes grid connection project in Suqian, Jiangsu Province IHRT 10.00% – News: Partners with Roc Nation and JAY-Z for radio launch of JAY-Z's new album PTRC 5.78% – News: Participates in drilling of second exploration well in Kern County, California FSC 4.74% – News: Focus of Fifth Street Asset Management’s (NASDAQ: FSAM) strategic discussions BLIN 3.25% – News: Moves on momentum from recently being selected as a digital experience…

FridayJun 30, 2017 1:19 pm

NetworkNewsBreaks – Aeterna Zentaris, Inc. (NASDAQ: AEZS) Resubmits NDA for Macrilen™ for the Evaluation of AGHD in Adults

Aeterna Zentaris (NASDAQ: AEZS) shares are higher after the company this morning said that is has resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Macrilen™ for the evaluation of growth hormone deficiency in adults (AGHD). The resubmission comes ahead of the company’s previously announced schedule, and the company anticipates an FDA review period of six months. “We anticipate successful FDA approval and, as a result, we continue to build our commercial organization and infrastructure in preparation for the earliest possible launch of Macrilen™. Our focus is to be prepared to launch…

FridayJun 30, 2017 12:45 pm

NetworkNewsBreaks – ORHub, Inc. (ORHB) Driving Health Care Cost Reduction of Up to 40% with Value-Based Software

Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) was featured in a recent case study evaluating the value of its innovative platform at the Hoag Orthopedic Institute (HOI). Among the highlights from the study, researchers found that, by leveraging Microsoft Azure intelligence and analytics, ORHub is capable of helping medical providers achieve cost efficiencies of as much as 40 percent while simultaneously driving closure of reimbursement gaps. The significance of these potential savings is reinforced when studying current health care expenditures in the U.S., which exceed $3 trillion annually and account for roughly 17 percent of GDP. ORHub’s research indicates…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks